Abingworth, a trans-atlantic bio-science investment firm, led a $150m funding round in Pathalys Pharma, a private, late-stage biopharma company, with participation from Carlyle, OrbiMed, Catalys Pacific and DaVita Venture Group. "Pathalys is very excited to collaborate with Launch Tx and to have the backing of such an esteemed group of healthcare investors. Through this collaboration and transaction, Pathalys expects to be fully funded through the completion of its planned phase 3 trials, and pre-commercialization efforts for upacicalcet. We look forward to working closely with Launch Tx to advance upacicalcet toward registration in the US with the goal of making this important product candidate available for dialysis patients with SHPT," Neal Fowler, Pathalys CEO.